COMMUNIQUÉS West-GlobeNewswire

Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update
03/03/2026
Significant achievements in 2025, enabling multiple near-term clinical milestones across late-stage portfolio, starting with the forthcoming topline results from DIAMOND Phase 3 trials with OCS-01 eye drops in diabetic [...]
InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement
03/03/2026
NEW YORK and HERZLIYA, Israel, March 03, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (Nasdaq: INCR) (TASE: INCR) (“ InterCure ” or the “ Company ”) today announced that on February 25, 2026 the Company received a written [...]
Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2026 American Academy of Pain Medicine PainConnect Annual Meeting
03/03/2026
CHATHAM, N.J., March 03, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated, commercial biotechnology company, announced today that a poster on [...]
Vaxart to Host Upcoming Conference Calls
03/03/2026
Full year 2025 business update and financial results conference call to be held March 12 at 4:30 p.m. ET Stockholder fireside chat to be held on March 13 at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., March 03, 2026 ( [...]
Information relative au nombre total des droits de vote et d’actions composant le capital social au 28 février 2026
03/03/2026
Information relative au nombre total des droits de vote et d’actions composant le capital social au 28 février 2026 (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) Place de cotation : NYSE [...]
Sana Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates
03/03/2026
Shared 12-month clinical results of ongoing UP421 type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression are safe and well-tolerated, evade detection by the [...]
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
03/03/2026
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appeal If the $1.3 billion payment is realized, this settlement [...]
Dentsply Sirona to Participate in the Leerink Partners Global Healthcare Conference 2026
03/03/2026
CHARLOTTE, N.C., March 03, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will participate in the Leerink Partners Global Healthcare [...]
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026
03/03/2026
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers ) Market : NYSE [...]
Roivant Announces Genevant Sciences’ and Arbutus Biopharma’s $2.25 Billion Global Settlement With Moderna
03/03/2026
Moderna to pay Genevant and Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appeal If the $1.3 billion payment is realized, this settlement [...]
ProQR Announces Webcast of Presentation at the 2026 Citizens Life Sciences Conference
03/03/2026
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its [...]
Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference
03/03/2026
SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)- [...]
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026
03/03/2026
DEER PARK, Ill., March 03, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare [...]
Castle Biosciences Announces Grand Opening of New Corporate Headquarters in Friendswood, Texas
03/03/2026
FRIENDSWOOD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will host a grand [...]
Quipt Home Medical Announces Voting Results From Special Meeting of Shareholders
03/03/2026
CINCINNATI, March 03, 2026 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “ Company ”) (NASDAQ: QIPT; TSX: QIPT)‎, a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced [...]
ATI Advisory Welcomes Former Wisconsin Medicaid Director Bill Hanna as Practice Director of Payer Strategy and Program Design
03/03/2026
Washington, DC, March 03, 2026 (GLOBE NEWSWIRE) -- ATI Advisory (ATI), a leading healthcare consulting firm, today announced that Bill Hanna has joined the firm as Practice Director of Payer Strategy and Program Design [...]
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/03/2026
SAN FRANCISCO, March 03, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and [...]
Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results
03/03/2026
Spin-off of biopharma operations into a public company to be called “First Tracks Biotherapeutics” on track for Q2 2026, potentially as early as late-April Phase 1b enrollment ongoing in celiac disease and trial cohort [...]
Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug
03/03/2026
Blackstone Life Sciences will provide $400 million to support development of duvakitug, a human monoclonal antibody targeting TL1A Duvakitug is currently in phase 3 clinical studies for ulcerative colitis (UC) and Crohn [...]

Pages